Anavex announces new publication on blarcamesine in Alzheimer’s

Anavex (AVXL) Life Sciences reported a peer-reviewed publication in the journal Neuroscience Letters, titled “Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer’s disease model.” This study shows that a pre-treatment with blarcamesine prevented Amyloid beta-induced memory impairment and brain oxidative injury suggesting that blarcamesine is an attractive candidate for Alzheimer’s disease pharmacological prevention. “This preclinical study is exciting since it clearly demonstrates a preventative effect of blarcamesine in Alzheimer’s pathology and potentially might be able to prevent onset of Alzheimer’s disease in healthy individuals,” said Tangui Maurice, PhD, Research Director at University of Montpellier, France and author of the publication. “These findings support the future direction of clinical trials with the objective of addressing blarcamesine’s potential as a safe and effective pharmacologic agent – applied as convenient once-daily oral pill – for the prevention of Alzheimer’s disease.”